{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:40:31Z","timestamp":1782549631051,"version":"3.54.5"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Singapore Ministry of Health\u2019s National Medical Research Council under its National Medical Research Council (NMRC) Clinician Scientist Award Senior Investigator Grant","award":["CSASI21jun-0003"],"award-info":[{"award-number":["CSASI21jun-0003"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Selinexor (SEL) is an oral inhibitor of nuclear export protein Exportin 1 (XPO1) previously shown to upregulate programmed cell death protein 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To investigate the safety and antitumor activity of SEL, nivolumab (NIVO), and ipilimumab (IPI) in Asian patients with treatment-refractory solid organ cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Phase I study of escalating doses of SEL in combination with NIVO\u2009+\u2009IPI. Patients were enrolled in a 3\u2009+\u20093 design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>NIVO and IPI were dosed at 240\u2009mg Q2W and 1\u2009mg\/kg Q6W, respectively. SEL was dosed with a 2-week monotherapy run-in prior to triplet therapy, at dose levels (DL) 1 (40\u2009mg once\/week) and DL2 (60\u2009mg once\/week). Dose-limiting toxicity (DLT) was assessed over the first 6\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twelve patients were enrolled; 11 were evaluable for response, and 6 were evaluable for DLT (1 had a non-treatment-related stroke and 5 had progressive disease (PD) prior to completion of the DLT period). The median age was 64.5 (range 39\u201378)\u2009years. The median line of prior therapy was 3 (range 2\u20135). Dose escalation proceeded through DL1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20097, 3 evaluable for DLT) and DL2 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20095, 3 evaluable for DLT). No DLTs were observed among evaluable patients. No patients required dose reduction of SEL. Most frequent treatment-related AEs were fatigue (5\/12;\n                      <jats:italic toggle=\"yes\">G<\/jats:italic>\n                      \u2009\u2a7e\u20093\u2009=\u20091), nausea (5\/12;\n                      <jats:italic toggle=\"yes\">G<\/jats:italic>\n                      \u2009\u2a7e\u20093\u2009=\u20090), anorexia (4\/12;\n                      <jats:italic toggle=\"yes\">G<\/jats:italic>\n                      \u2009\u2a7e\u20093\u2009=\u20090), transaminitis (2\/12;\n                      <jats:italic toggle=\"yes\">G<\/jats:italic>\n                      \u2009\u2a7e\u20093\u2009=\u20090), and hypomagnesemia (2\/12;\n                      <jats:italic toggle=\"yes\">G<\/jats:italic>\n                      \u2009\u2a7e\u20093\u2009=\u20090). The recommended phase II dose was SEL 60\u2009mg once\/week combined with NIVO\u2009+\u2009IPI. One patient had a partial response (PR; progression-free survival (PFS) of 61\u2009days), 3 had prolonged stable disease (SD; PFS of 141, 344, and 442\u2009days, respectively), and 7 had PD. All patients with SD or PR had previously progressed on immunotherapy but experienced prolonged disease control on SEL in combination with NIVO\u2009+\u2009IPI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>SEL in combination with NIVO\u2009+\u2009IPI was well tolerated without any new safety signals. The combination showed promising and durable antitumor activity in Asian patients with advanced malignancies who had failed prior immunotherapy and merits further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>\n                      NCT04850755 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04850755\">https:\/\/clinicaltrials.gov\/study\/NCT04850755<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251339930","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:04:57Z","timestamp":1749459897000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced\/metastatic solid malignancies"],"prefix":"10.1177","volume":"17","author":[{"given":"Joan","family":"R. Choo","sequence":"first","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhiay Nathan","family":"Jeraj","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-1368","authenticated-orcid":false,"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Peng","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugarajah","family":"Asokumaran","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria H. J.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Y. L.","family":"Ngoi","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"NUS Centre for Cancer Research, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L. A.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Ean","family":"Chee","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joline S. J.","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Cher","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"},{"name":"Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Chin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, Singapore, Singapore"},{"name":"Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David S. P.","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2013Oncology, National University Health System, National University Cancer Institute, 1E Kent Ridge Road, National University Health System Tower Block Level 7, Singapore 119228, Singapore"},{"name":"Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0007-y"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0484"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-1005"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0858"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0416"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0498"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164443"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8121"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-2319"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-LB-086"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302750"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30624-6"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01998"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","unstructured":"FDA. Full prescribing information for selinexor https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212306Orig1s013lbl.pdf (2025 accessed 16 March 2025).","DOI":"10.22233\/20412495.0325.1"},{"key":"e_1_3_4_21_2","article-title":"Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT dose-finding extension (CONSORT-DEFINE) guidance","volume":"383","author":"Yap C","year":"2023","unstructured":"Yap C, Solovyeva O, de Bono J, et al. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT dose-finding extension (CONSORT-DEFINE) guidance. BMJ 2023; 383: e076387.","journal-title":"BMJ"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01015"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00533"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01503"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1808"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3949"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221087555"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34820"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad241"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1247"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.086"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02906"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.36_suppl.427956"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101179"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5953"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251339930","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251339930","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251339930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:32:20Z","timestamp":1777588340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251339930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"alternative-id":["10.1177\/17588359251339930"],"URL":"https:\/\/doi.org\/10.1177\/17588359251339930","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17588359251339930"}}